AI-Driven Robotic Automation for Cell Therapy Manufacturing
Delivered in partnership with Streamline Bio

Early Adopter and Design Partner Program
Made Scientific and Streamline Bio are building an integrated CDMO and automation offering for therapeutic developers. The Early Adopter Program focuses on CAR-T therapies in early- to late-phase development.
- Why CAR-T: complex, multi-step workflows can amplify variability and operational risk
- Where we are today: Made Scientific is Streamline Bio’s exclusive early adopter, design partner, and preferred CDMO partner
- What’s next: co-developing and validating automated workflows in a GMP-ready environment, including new unit operations and enhanced data capture
How Streamline Bio Automation Fits into Cell Therapy Manufacturing
Initial focus: CAR-T workflows
Streamline Bio’s modular robotics are designed to integrate into existing infrastructure and support diverse equipment and protocols with minimal disruption.
- Standardize labor-intensive steps to reduce execution variability
- Improve traceability for deviations, investigations, and comparability
- Enable repeatable workflows for scale-up across suites
What Clients Can Expect
Automation that fits existing cleanrooms
CDMO execution aligned to development and scale
Data capture that supports GMP expectations
Repeatability across suites and shifts
Why Partner with Made Scientific + Streamline Bio
Streamline Bio automation, deployed with Made Scientific
- Autonomous, modular robotics built for cell therapy manufacturing
- Validated in a live production environment at Made Scientific’s Princeton, New Jersey facility
- Designed to integrate with common cell therapy equipment including CliniMACS Prodigy®, G-Rex®, and LOVO®
Integrated CDMO services, automation-ready by design
- One team for evaluation, integration planning, and tech transfer
- Structured, GMP-aligned documentation practices
Engagement Models Built for Speed and Control
Choose the engagement model that matches your internal capabilities and the level of hands-on collaboration you want during automation evaluation and deployment:
- Fee-for-service executionBest for defined studies with clear deliverables and timelines.
- Dedicated team executionBest for sustained development support, rapid iteration, and parallel workstreams.
- Hybrid client-in-plant operationsBest for joint execution, on-site knowledge transfer, and shared process ownership.
- Early Adopter collaborationBest for teams co-developing automation workflows and extending capability across unit operations.
Made Scientific and Streamline Bio Launch Exclusive Early Adopter Program to Advance AI-Driven Robotic Automation for Cell Therapy Manufacturing
In February 2026, the two companies launched an exclusive Early Adopter Program to accelerate autonomous manufacturing workflows for GMP cleanroom environments.
Made Scientific and Streamline Bio Announce Collaboration to Accelerate AI-Driven Robotic Manufacturing for Cell Therapies
In October 2025, Made Scientific and Streamline Bio announced successful initial validation of Streamline Bio’s AI-driven precision robotics in a live cell therapy production environment at Made Scientific’s Princeton facility. Learn how the collaboration is advancing toward GMP integration and early adopter programs.
More partners
RoosterBio
MSC and extracellular vesicle platforms integrated into Made Scientific’s development and manufacturing services, from process development through commercial supply.
Pluristyx
Clinical-grade iPSC lines and derivative cell types paired with Made Scientific’s process development and manufacturing expertise to support progression toward the clinic.
Syenex
RapidCell™ vector technology powers MadeFast™, Made Scientific’s single-step CAR-T platform designed to reduce manufacturing time, cost, and complexity.
CARR Biosystems
UniFuge® single-use centrifugation integrated across Made Scientific's Princeton and East Norriton facilities for scalable MSC manufacturing.
See the Automation in Action
Get a closer look at the Streamline Bio robotic platform and find out whether your CAR-T therapy is a fit for the Early Adopter Program.